Ulipristal acetate is a new oral emergency contraceptive

Ulipristal acetate is a new oral emergency contraceptive that is the active chemical component of Ella, a new generation of emergency contraceptives currently on the market in the United States. It can not only be used for up to 120 hours after unprotected sexual intercourse, and the efficacy of emergency contraception does not decrease with the delay of medication, while safety and tolerability are good. Compared with levonorgestrel, the most commonly used emergency contraceptive, Ulipristal acetate has a wider clinical applicability and has the potential to prevent more unwanted pregnancies.
Ulipristal acetate was developed by HRA Pharmaceuticals and was approved by the US Food and Drug Administration in August 2010 under the trade name Ella. For unprotected sexual activity or prevention of pregnancy within 120 hours of known or suspected contraceptive failure. Ulipristal acetate is a selective progesterone receptor modulator that exerts emergency contraception primarily by inhibiting ovulation. The study found that Ulipristal acetate inhibited sputum excretion more effectively than levonorgestrel when administered near the day of sputum (the highest chance of conception), suggesting that Ulipristal acetate may have a stronger emergency contraceptive effect.